Abstract
Simvastatin, is a lipid regulating drug, which is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), obtained by synthesis from lovastatin. It is indicated in the treatment of hyperlipidemias, including hypercholesterolaemias, combined mixed hyperlipidemia hyperlipoproteinemias, hypertriglyceridemia, and primary dysbetalipoproteinemia. This review describes a brief overview of the chemistry including impurities and different synthetic schemes, pharmacokinetic, pharmacodynamic and adverse effect of simvastatin as well as the recent trends in drug–drug interaction studies of simvastatin with various drug categories such as antibacterials, anticoagulants, antidepressants, antifungals, antivirals, calcium-channel blockers, immunosuppressants, lipid regulating drugs and grapefruit juice. This review also focuses distinctly on comprehensive update of various analytical methods for the quantification of simvastatin and/or its metabolites, impurities, degradants and other drugs.
Keywords: Analytical methods, impurities, pharmacodynamics, pharmacokinetics and simvastatin, hypercholesterolaemias, immunosuppressants, degradants, antifungals, antidepressants
Current Pharmaceutical Analysis
Title:Simvastatin: Review of Updates on Recent Trends in Pharmacokinetics, Pharmacodynamics, Drug–drug Interaction, Impurities and Analytical Methods
Volume: 8 Issue: 2
Author(s): Pawan Kumar Basniwal and Deepti Jain
Affiliation:
Keywords: Analytical methods, impurities, pharmacodynamics, pharmacokinetics and simvastatin, hypercholesterolaemias, immunosuppressants, degradants, antifungals, antidepressants
Abstract: Simvastatin, is a lipid regulating drug, which is a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), obtained by synthesis from lovastatin. It is indicated in the treatment of hyperlipidemias, including hypercholesterolaemias, combined mixed hyperlipidemia hyperlipoproteinemias, hypertriglyceridemia, and primary dysbetalipoproteinemia. This review describes a brief overview of the chemistry including impurities and different synthetic schemes, pharmacokinetic, pharmacodynamic and adverse effect of simvastatin as well as the recent trends in drug–drug interaction studies of simvastatin with various drug categories such as antibacterials, anticoagulants, antidepressants, antifungals, antivirals, calcium-channel blockers, immunosuppressants, lipid regulating drugs and grapefruit juice. This review also focuses distinctly on comprehensive update of various analytical methods for the quantification of simvastatin and/or its metabolites, impurities, degradants and other drugs.
Export Options
About this article
Cite this article as:
Kumar Basniwal Pawan and Jain Deepti, Simvastatin: Review of Updates on Recent Trends in Pharmacokinetics, Pharmacodynamics, Drug–drug Interaction, Impurities and Analytical Methods, Current Pharmaceutical Analysis 2012; 8 (2) . https://dx.doi.org/10.2174/1573412911208020135
DOI https://dx.doi.org/10.2174/1573412911208020135 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology Patent Selections:
Recent Patents on Regenerative Medicine Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology Exercise as a platform for pharmacotherapy development in cardiac diseases
Current Pharmaceutical Design Editorial (Hot Topic: Novel Biomarkers in the Prognosis, Progression and Treatment of Cardiovascular Disease: The Role of microRNAs )
Current Topics in Medicinal Chemistry Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Does Daily Dialysis Improve Hypertension in Chronic Haemodialysis Patients?
Current Hypertension Reviews Palliative Combined Percutaneous Balloon Aortic Valvuloplasty and Unprotected Left Main Stenting in End Stage Renal Disease
Current Cardiology Reviews Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Multi-target Activities of Selected Alkaloids and Terpenoids
Mini-Reviews in Organic Chemistry Physiological Functions of Heat Shock Proteins
Current Protein & Peptide Science Personalized Medicine, Bioethics and Social Responsibilities: Re-thinking the Pharmaceutical Industry to Remedy Inequities in Patient Care and International Health
Current Pharmacogenomics and Personalized Medicine Therapeutic Targets for Heart Failure: Beyond Beta-Adrenergic and Renin-Angiotensin System Blockade
Recent Patents on Cardiovascular Drug Discovery Inflammation, Adiponectin, Obesity and Cardiovascular Risk
Current Medicinal Chemistry Arrhythmia Pharmacogenomics: Methodological Considerations
Current Pharmaceutical Design C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?
Current Pharmaceutical Design From Early Origins. When and Why does Asthma Develop?
Current Pediatric Reviews Premature Cardiovascular Disease in Women with Lupus and Relationship to Disease Severity
Current Women`s Health Reviews In-Vitro and In-Vivo Pharmacological Activities with Phytochemical Evaluation of Methanolic Extract of Microcos paniculata Stem Barks
Current Drug Therapy